DalsnaFinance

Zimmer Biomet $ZBH

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Indiana
Create a scorecard
$95.32
+0.33 (+0.35%)
As of Oct 20, 2026, 12:57 PM EDT · cached
Price history
Loading chart…

Key facts

52-week range (closes)
$79.58 – $103.98 Lowest close May 11, 2026, highest Oct 22, 2025; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends
December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since
Aug 7, 2001 · All S&P 500 changes

Zimmer Biomet (ZBH) is trading up at $95.32 (+0.35%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Zimmer Biomet revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$8.23B$3.93B−$379.2MFY2016 revenue: $7.68BFY2016 net income: $305.9M · Net margin 4.0%'16FY2017 revenue: $7.82BFY2017 net income: $1.81B · Net margin 23.2%'17FY2018 revenue: $7.93BFY2018 net income: −$379.2M · Net margin −4.8%'18FY2019 revenue: $7.98BFY2019 net income: $1.13B · Net margin 14.2%'19FY2020 revenue: $6.13BFY2020 net income: −$138.9M · Net margin −2.3%'20FY2021 revenue: $6.83BFY2021 net income: $401.6M · Net margin 5.9%'21FY2022 revenue: $6.94BFY2022 net income: $231.4M · Net margin 3.3%'22FY2023 revenue: $7.39BFY2023 net income: $1.02B · Net margin 13.8%'23FY2024 revenue: $7.68BFY2024 net income: $903.8M · Net margin 11.8%'24FY2025 revenue: $8.23BFY2025 net income: $705.1M · Net margin 8.6%'250%20%40%60%FY2016 net margin: 4.0%FY2017 net margin: 23.2%FY2018 net margin: −4.8% (off the scale, which stops at −2.8%)FY2019 net margin: 14.2%FY2020 net margin: −2.3%FY2021 net margin: 5.9%FY2022 net margin: 3.3%FY2023 net margin: 13.8%FY2024 net margin: 11.8%FY2025 net margin: 8.6%
Zimmer Biomet annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$7.68B$7.82B$7.93B$7.98B$6.13B$6.83B$6.94B$7.39B$7.68B$8.23B
Growth (year over year)+28.1%+1.8%+1.4%+0.6%−23.2%+11.4%+1.6%+6.5%+3.8%+7.2%
Gross profit$5.30B$5.69B$5.66B$5.73B$4.30B$4.87B$4.92B$5.31B$5.49B$5.74B
Gross margin69.0%72.7%71.4%71.8%70.2%71.3%70.9%71.8%71.5%69.7%
Operating income$821.1M$799.3M$33.8M$1.14B$83.1M$860.3M$696.3M$1.28B$1.29B$1.10B
Operating margin10.7%10.2%0.4%14.3%1.4%12.6%10.0%17.3%16.7%13.3%
Net income$305.9M$1.81B−$379.2M$1.13B−$138.9M$401.6M$231.4M$1.02B$903.8M$705.1M
Net margin4.0%23.2%−4.8%14.2%−2.3%5.9%3.3%13.8%11.8%8.6%
EPS (diluted)$1.51$8.90−$1.86$5.47−$0.67$1.91$1.10$4.88$4.43$3.55
Balance sheet
Cash and equivalents$634.1M$524.4M$542.8M$617.9M$802.1M$378.1M$375.7M$415.8M$525.5M$591.9M
Total assets$26.7B$26.0B$24.1B$24.6B$24.4B$23.5B$21.1B$21.5B$21.4B$23.1B
Total liabilities$17.0B$14.3B$12.9B$12.2B$12.2B$10.8B$9.04B$9.01B$8.89B$10.4B
Long-term debt$10.7B$8.92B$8.41B$6.72B$7.63B$5.46B$5.15B$4.87B$5.34B$6.93B
Shareholders' equity$9.67B$11.7B$11.3B$12.4B$12.2B$12.7B$12.0B$12.5B$12.5B$12.7B
Cash flow
Operating cash flow$1.63B$1.58B$1.75B$1.59B$1.20B$1.50B$1.36B$1.58B$1.50B$1.70B
Capital expenditure$184.7M$156.0M$162.7M$207.1M$111.9M$143.6M$187.9M$291.1M$203.8M$224.5M
Free cash flow$1.45B$1.43B$1.58B$1.38B$1.09B$1.36B$1.17B$1.29B$1.30B$1.47B
Dividends paid$188.4M$193.6M$195.2M$196.7M$198.5M$200.1M$201.2M$200.9M$196.0M$190.3M
Share buybacks$415.5M—————$126.4M$692.2M$868.0M$487.0M

From Zimmer Biomet's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Zimmer Biomet vs the Health Care sector and the S&P 500

Zimmer Biomet's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Zimmer Biomet compared with the median Health Care company and the median S&P 500 company
MeasureZimmer BiometHealth Care (59 other S&P 500 companies)S&P 500 (502 other companies)
Revenue growth, latest fiscal year+7.2%+7.1%+7.0%
Net margin, latest fiscal year8.6%13.1%13.0%
Dividend per share, latest fiscal year$0.96$2.48$2.40
Share price change, 1 year−7.5%+19.8%+5.9%

Zimmer Biomet: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Zimmer Biomet included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

Source: Wikipedia — Zimmer Biomet

Headquarters
Warsaw, Indiana From SEC filings, Oct 2026

Recent News (15)

More Health Care stocks

Browse all companies →